230 related articles for article (PubMed ID: 29507461)
1. Practical management of toxicities associated with targeted therapies for advanced gastroenteropancreatic neuroendocrine tumors.
Cuyle PJ; Prenen H
Ann Gastroenterol; 2018; 31(2):140-150. PubMed ID: 29507461
[TBL] [Abstract][Full Text] [Related]
2. Systemic therapies for advanced gastroenteropancreatic neuroendocrine tumors.
Patel D; Chan D; Cehic G; Pavlakis N; Price TJ
Expert Rev Endocrinol Metab; 2016 Jul; 11(4):311-327. PubMed ID: 30058926
[TBL] [Abstract][Full Text] [Related]
3. Management of Well-differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEPNETs): A Review.
Pasricha G; Padhi P; Daboul N; Monga DK
Clin Ther; 2017 Nov; 39(11):2146-2157. PubMed ID: 29173655
[TBL] [Abstract][Full Text] [Related]
4. Comparative safety review of the current therapies for gastroenteropancreatic neuroendocrine tumors.
Koffas A; Toumpanakis C
Expert Opin Drug Saf; 2021 Mar; 20(3):321-334. PubMed ID: 33338383
[No Abstract] [Full Text] [Related]
5. Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline.
Del Rivero J; Perez K; Kennedy EB; Mittra ES; Vijayvergia N; Arshad J; Basu S; Chauhan A; Dasari AN; Bellizzi AM; Gangi A; Grady E; Howe JR; Ivanidze J; Lewis M; Mailman J; Raj N; Soares HP; Soulen MC; White SB; Chan JA; Kunz PL; Singh S; Halfdanarson TR; Strosberg JR; Bergsland EK
J Clin Oncol; 2023 Nov; 41(32):5049-5067. PubMed ID: 37774329
[TBL] [Abstract][Full Text] [Related]
6. Therapy Resistant Gastroenteropancreatic Neuroendocrine Tumors.
McClellan K; Chen EY; Kardosh A; Lopez CD; Del Rivero J; Mallak N; Rocha FG; Koethe Y; Pommier R; Mittra E; Pegna GJ
Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230691
[TBL] [Abstract][Full Text] [Related]
7. Medical Management of Gastroenteropancreatic Neuroendocrine Tumors.
Chandrasekharan C
Surg Oncol Clin N Am; 2020 Apr; 29(2):293-316. PubMed ID: 32151362
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic strategies for patients with neuroendocrine neoplasms: current perspectives.
Modica R; Liccardi A; Minotta R; Cannavale G; Benevento E; Colao A
Expert Rev Endocrinol Metab; 2022 Sep; 17(5):389-403. PubMed ID: 35822906
[TBL] [Abstract][Full Text] [Related]
9. Systemic treatment of neuroendocrine tumors with hepatic metastases.
Demirkan BH; Eriksson B
Turk J Gastroenterol; 2012; 23(5):427-37. PubMed ID: 23161287
[TBL] [Abstract][Full Text] [Related]
10. Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas.
Fazio N; Cinieri S; Lorizzo K; Squadroni M; Orlando L; Spada F; Maiello E; Bodei L; Paganelli G; Delle Fave G; de Braud F
Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S87-94. PubMed ID: 21129617
[TBL] [Abstract][Full Text] [Related]
11. Systemic Therapy of Advanced Well-differentiated Small Bowel Neuroendocrine Tumors Progressive on Somatostatin Analogues.
Agarwal P; Mohamed A
Curr Treat Options Oncol; 2022 Sep; 23(9):1233-1246. PubMed ID: 35939200
[TBL] [Abstract][Full Text] [Related]
12. Gastroenteropancreatic Neuroendocrine Tumors.
Cives M; Strosberg JR
CA Cancer J Clin; 2018 Nov; 68(6):471-487. PubMed ID: 30295930
[TBL] [Abstract][Full Text] [Related]
13. Neuroendocrine Tumor Therapy with Lutetium-177: A Literature Review.
Maqsood MH; Tameez Ud Din A; Khan AH
Cureus; 2019 Jan; 11(1):e3986. PubMed ID: 30972265
[TBL] [Abstract][Full Text] [Related]
14. Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumors.
Delaunoit T; Rubin J; Neczyporenko F; Erlichman C; Hobday TJ
Mayo Clin Proc; 2005 Apr; 80(4):502-6. PubMed ID: 15819288
[TBL] [Abstract][Full Text] [Related]
15. [Pharmacologic therapy for neuroendocrine tumours].
Petrányi A; Bodoky G
Orv Hetil; 2011 Mar; 152(10):379-91. PubMed ID: 21354954
[TBL] [Abstract][Full Text] [Related]
16. Treatment of gastroenteropancreatic neuroendocrine tumors with peptide receptor radionuclide therapy.
van Vliet EI; Teunissen JJ; Kam BL; de Jong M; Krenning EP; Kwekkeboom DJ
Neuroendocrinology; 2013; 97(1):74-85. PubMed ID: 22237390
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic Options for Neuroendocrine Tumors: A Systematic Review and Network Meta-analysis.
Kaderli RM; Spanjol M; Kollár A; Bütikofer L; Gloy V; Dumont RA; Seiler CA; Christ ER; Radojewski P; Briel M; Walter MA
JAMA Oncol; 2019 Apr; 5(4):480-489. PubMed ID: 30763436
[TBL] [Abstract][Full Text] [Related]
18. Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.
Mujica-Mota R; Varley-Campbell J; Tikhonova I; Cooper C; Griffin E; Haasova M; Peters J; Lucherini S; Talens-Bou J; Long L; Sherriff D; Napier M; Ramage J; Hoyle M
Health Technol Assess; 2018 Sep; 22(49):1-326. PubMed ID: 30209002
[TBL] [Abstract][Full Text] [Related]
19. Medical Management of Gastroenteropancreatic Neuroendocrine Tumors: Current Strategies and Future Advances.
Mohamed A; Strosberg JR
J Nucl Med; 2019 Jun; 60(6):721-727. PubMed ID: 30737297
[TBL] [Abstract][Full Text] [Related]
20. Current status of medical treatment for gastroenteropancreatic neuroendocrine neoplasms and future perspectives.
Hijioka S; Morizane C; Ikeda M; Ishii H; Okusaka T; Furuse J
Jpn J Clin Oncol; 2021 Aug; 51(8):1185-1196. PubMed ID: 34038547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
